Loading...

3-D Matrix, Ltd.

7777.T•JPX
Healthcare
Medical - Devices
¥197.00
¥4.00(2.07%)

3-D Matrix, Ltd. (7777.T) Stock Overview

Explore 3-D Matrix, Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 64.4/100

Key Financials

Market Cap21.7B
P/E Ratio-21.18
EPS (TTM)$-25.20
ROE-0.65%
Fundamental Analysis

AI Price Forecasts

1 Week$153.15
1 Month$124.35
3 Months$125.68
1 Year Target$101.48

7777.T Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of 3-D Matrix, Ltd. (7777.T) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 50.63, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $101.48.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -21.18 and a market capitalization of 21.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

50.63RSI (14)
1.49MACD
31.56ADX
Stats data is not available for 7777.TStats details for 7777.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 7777.TAnalyst Recommendations details for 7777.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

3-D Matrix, Ltd. develops self-assembling peptide technology. It offers PuraMatrix, a self-assembling peptide hydrogel for use in the fields of regenerative medicine, cell therapy, drug delivery technology, and surgical treatment. The company was founded in 2004 and is based in Tokyo, Japan.

CEO

Jun Okada

Employees

106

Headquarters

Kojimachi HF Building, Tokyo

Founded

2011

Frequently Asked Questions

;